Clinical trials
Brain Metastases From Non-small Cell Lung Cancer (NSCLC) clinical trials
Below are recruiting brain metastases from non-small cell lung cancer (nsclc) clinical trials, each written for real people, not researchers. We’re tracking 274 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07373951Enrolling by invitation
Predicting cancer gene status from MRI scans in brain metastasis
This trial uses brain MRI scans and deep learning to predict whether non-small cell lung cancer that has spread to the brain has certain gene changes (EGFR or ALK). Knowing this may help guide treatment without needing additional tissue testing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07371663RecruitingPhase 1/Phase 2
TCC1727 combination therapy for advanced solid tumors
This trial tests a new drug, TCC1727, combined with other treatments for people with advanced solid tumors that have stopped responding to standard therapy. It aims to see if these combinations can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07362459RecruitingPhase 3
Study of SCTB14 for untreated advanced non-small cell lung cancer
This trial tests a new drug, SCTB14, as a first treatment for advanced non-small cell lung cancer that has a high level of PD-L1. It aims to see if the drug is safe and effective for people who haven't had other treatments for their cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07361705RecruitingPhase 1
Zorifertinib and osimertinib for lung cancer that spread to the brain lining
This trial tests a new drug, zorifertinib, combined with osimertinib for people whose lung cancer has spread to the lining of the brain (meninges) and continued to grow despite osimertinib treatment. The goal is to see if this combination can better control the brain spread.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07361237RecruitingPhase 1
HJ-004-02 tablet for EGFR-mutated lung cancer
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07355205RecruitingPhase 1/Phase 2
Combination immunotherapy for advanced lung cancer
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
St Louis, MissouriAges 18 years+ - NCT04777084RecruitingPhase 2
Lenvatinib plus PD-1 antibody for advanced lung cancer
This Phase 2 study tests whether a combination of lenvatinib and a PD-1/PD-L1–blocking antibody (IBI318) can shrink advanced non-small cell lung cancer and is safe to use. It targets people whose cancer has specific genetic changes or specific prior treatment history, based on three different study groups.
Changsha, HunanAges 18–75 - NCT07336732RecruitingPhase 2
New targeted drug with chemo for rare EGFR lung cancer
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
GuangzhouAges 18 years+ - NCT07330050RecruitingPhase 2
Combination treatment for advanced lung cancer after immunotherapy failure
This trial tests a combination of WAST Cell therapy and the chemotherapy drug docetaxel for people with advanced non-small cell lung cancer whose cancer progressed after treatment with a PD-1 inhibitor. The goal is to see if this combination can help shrink tumors and extend survival.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07330596RecruitingPhase 2
Study of QL1706 plus chemo for lung cancer that got worse after immunotherapy
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
HefeiAges 18–75 - NCT07323641RecruitingPhase 2
Telisotuzumab Vedotin and Osimertinib for Advanced Lung Cancer
This trial tests a combination of two drugs—telisotuzumab vedotin and osimertinib—for people with a specific type of advanced non-small cell lung cancer that has stopped responding to osimertinib alone. The goal is to see if adding the second drug can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07322341RecruitingPhase 2
Study of SX-682 with atezolizumab for advanced lung cancer
This trial tests a new drug combination (SX-682 plus atezolizumab) for people with advanced non-small cell lung cancer that has grown after standard treatments like immunotherapy and chemotherapy. It aims to see if the combination can help shrink or slow the cancer.
Seattle, WashingtonAges 18 years+ - NCT07291037RecruitingPhase 3
Comparing a new drug to standard chemo for advanced lung cancer
This trial tests a new drug called datopotamab deruxtecan against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has already been treated. The new drug targets a protein called TROP2 found on cancer cells, which may help slow or stop the cancer's growth.
Chandler, ArizonaAges 18 years+ - NCT07288177RecruitingPhase 2
A study of Rina-S for people with non-small cell lung cancer
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Fountain Valley, CaliforniaAges 18 years+ - NCT07285434Enrolling by invitationEarly Phase 1
Personalized vaccine for first-line advanced lung cancer
This study tests a personalized vaccine (Microlyvaq™) made just for your tumor, given together with standard chemo and immunotherapy (pembrolizumab). It is for people with advanced non-small cell lung cancer who have not yet started treatment for the advanced stage.
Thessaloniki, MacedoniaAges Any age - NCT07279935RecruitingPhase 4
Osimertinib plus chemotherapy for lung cancer that returned after osimertinib
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
BeijingAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Goodyear, ArizonaAges 18 years+ - NCT04852588Recruiting
Sample chest lymph nodes during treatment for advanced lung cancer
This study checks lymph nodes in the chest (using a camera-guided test) in people with advanced non-small cell lung cancer who are getting curative-intent radiation. The trial may help doctors better confirm how far the cancer has spread and guide the best radiation treatment plan.
London, OntarioAges 18 years+ - NCT07251582RecruitingPhase 3
Comparing infusion timing for lung cancer immunotherapy before surgery
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
Changsha, HunanAges 18–75 - NCT07231068RecruitingPhase 1/Phase 2
Dositinib tablets for advanced lung cancer with EGFR mutation
This trial tests a new targeted therapy, Dositinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to earlier EGFR-targeted drugs. It aims to find the best dose and see how well it shrinks tumors.
BeijingAges 18–75 - NCT07227025RecruitingPhase 1/Phase 2
Study of amivantamab and olomorasib for KRAS G12C lung cancer
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
San Diego, CaliforniaAges 18 years+ - NCT07222566RecruitingPhase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Bullhead City, ArizonaAges 18 years+ - NCT07217301RecruitingPhase 3
Comparing TAK-928 to docetaxel for advanced lung cancer
This study tests a new drug called TAK-928 against the standard chemo docetaxel for people with advanced squamous non-small cell lung cancer. You may be able to join if you have already tried a checkpoint inhibitor and platinum chemotherapy, and your cancer has grown.
Jonesboro, ArkansasAges 18 years+
Hear when a new Brain Metastases From Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for brain metastases from non-small cell lung cancer (nsclc)?
- Yes. Clin2 currently lists 274 recruiting brain metastases from non-small cell lung cancer (nsclc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a brain metastases from non-small cell lung cancer (nsclc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a brain metastases from non-small cell lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.